Cancer Diagnostics 2021: Supplier Shares and Market Segmnet Forecasts by TestsA Market on the Verge of ExplosionTechnological Breakthroughs, Emerging Tests, Competitive Intelligence [Report Updated: 23102017] Prices from USD $24500
Complete report $24,500.nbsp; DataPack test volumes, sales forecasts, supplier shares $15,900.
VPGMarketResearchrsquo;s new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the nextnbsp;five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USA
Worldwide Market Overview
Fiveyear test volume and sales projections by country.
Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers by country.
Estimated universe of laboratories performing cancer diagnostic testing by country.
Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.
Business Opportunities and Strategic Recommendations
Specific new product development opportunities with potentially
significant market appeal during the next five years.
Design criteria for new products.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Test
Biochemical Markers
Oncogenes
Growth Factors
Hormones
Colony Stimulating Factors
Lymphokines
Immunohistochemical Stains, and others.
ACTH, AFP, Beta2 Microglobulin, CA 153/27.29, CA 199, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, ColonSpecific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, NeuronSpecific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.
Supplier Shares, Sales and Volume Forecasts
Sales and market shares of major cancer diagnostic product
suppliers by individual test and country.
Fiveyear test volume and sales forecasts
for major tumor markers by country and market segment, including:
Hospitals
Commercial/Private Laboratories
Physician Offices/Group Practices
Cancer Clinics
Ambulatory Care Centers
Instrumentation Review
Analysis of major molecular diagnostic and immunodiagnostic analyzers
used for cancer testing, including their operating characteristics,
features and selling prices.
Technology Assessment
Assessment of latest molecular diagnostic methods,
biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,
chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies
and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.
Extensive listings of companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.
Competitive Strategies
Strategic assessments ofnbsp;major suppliers
and startup firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in Ramp;D.
The companies analyzed in the report include:
nbsp;nbsp; Abbott
nbsp;nbsp; AdnaGen
nbsp;nbsp; Agilent Technologies
nbsp;nbsp; Applied Gene Technologies
nbsp;nbsp; Arca Biopharma
nbsp;nbsp; Beckman Coulter/Danaher
nbsp;nbsp; Becton Dickinson
nbsp;nbsp; Biomedical Diagnostics
nbsp;nbsp; bioMerieux
nbsp;nbsp; BioRad
nbsp;nbsp; CellSearch
nbsp;nbsp; Cepheid
nbsp;nbsp; Correlogic Systems/Vermillion
nbsp;nbsp; Decode Genetics
nbsp;nbsp; Diadexus
nbsp;nbsp; Diagnocure
nbsp;nbsp; DiaSorin
nbsp;nbsp; Eiken Chemical
nbsp;nbsp; Elitech Group
nbsp;nbsp; Enterix
nbsp;nbsp; Enzo Biochem
nbsp;nbsp; Epigenomics
nbsp;nbsp; Fujirebio
nbsp;nbsp; Guided Therapeutics
nbsp;nbsp; Hologic/GenProbe
nbsp;nbsp; Kreatech/Leica
nbsp;nbsp; Kyowa Medex
nbsp;nbsp; Mackay Life Sciences
nbsp;nbsp; Myriad Genetics
nbsp;nbsp; OncoLab
nbsp;nbsp; OrthoClinical Diagnostics
nbsp;nbsp; Panacea Pharmaceuticals
nbsp;nbsp; Polartechnics
nbsp;nbsp; Polymedco
nbsp;nbsp; PreMD
nbsp;nbsp; Qiagen
nbsp;nbsp; Quest Diagnostics
nbsp;nbsp; Radient Pharmaceuticals
nbsp;nbsp; Roche
nbsp;nbsp; Scienion
nbsp;nbsp; Sequenom
nbsp;nbsp; Siemens Healthcare
nbsp;nbsp; Takara Bio
nbsp;nbsp; Targeted Diagnostics amp; Therapeutics
nbsp;nbsp; Thermo Fisher
nbsp;nbsp; Tosoh
nbsp;nbsp; Veridex
nbsp;nbsp; Wako Pure Chemicals
nbsp;nbsp; Wallac/PE
nbsp;nbsp; Zilla
Contains 1,200 pages and 450 tables
